KR20040075643A - Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof - Google Patents
Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof Download PDFInfo
- Publication number
- KR20040075643A KR20040075643A KR1020030011230A KR20030011230A KR20040075643A KR 20040075643 A KR20040075643 A KR 20040075643A KR 1020030011230 A KR1020030011230 A KR 1020030011230A KR 20030011230 A KR20030011230 A KR 20030011230A KR 20040075643 A KR20040075643 A KR 20040075643A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- powder
- sikhye
- malt
- Prior art date
Links
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 26
- 235000009566 rice Nutrition 0.000 title claims abstract description 26
- 240000007594 Oryza sativa Species 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title abstract description 15
- 235000009508 confectionery Nutrition 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 48
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 240000000249 Morus alba Species 0.000 claims abstract description 10
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 10
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 10
- 235000008397 ginger Nutrition 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 10
- 229940010454 licorice Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 244000111489 Gardenia augusta Species 0.000 claims description 8
- 241001106462 Ulmus Species 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000010411 cooking Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 abstract description 5
- 235000019634 flavors Nutrition 0.000 abstract description 5
- 235000019640 taste Nutrition 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000008213 purified water Substances 0.000 abstract description 2
- 241000209094 Oryza Species 0.000 abstract 4
- 241000949731 Ulmus davidiana Species 0.000 abstract 2
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 241000411851 herbal medicine Species 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 240000004670 Glycyrrhiza echinata Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102100027584 Protein c-Fos Human genes 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VYXAXCIILYRWDI-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O VYXAXCIILYRWDI-GEMLJDPKSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- GTDOPRQDTRLYAL-UHFFFAOYSA-N hydrogen peroxide;methanol Chemical compound OC.OO GTDOPRQDTRLYAL-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식혜에 관한 것으로, 더욱 상세하게는 엿기름 분말에 느릅나무 껍질 분말, 치자 분말, 갈근 분말, 뽕잎 분말, 감초 분말 및 생강 분말을 첨가한 후 열수추출하여 얻어지는 엿기름 액을 찹쌀 및 율무로부터 얻어지는 식혜밥에 첨가하여 당화시켜 제조되는 한방 식혜에 관한 것이다.The present invention relates to Sikhye, and more specifically, the malt liquid obtained by hot water extraction after adding elm bark powder, gardenia powder, brown root powder, mulberry leaf powder, licorice powder and ginger powder to malt powder is obtained from glutinous rice and yulmu. It is related to herbal Sikhye prepared by saccharification by addition to Sikhye rice.
식혜는 조선시대 이전부터 각 가정에서 크게 사랑받아 온 한국의 전통적 음료로서 단술 혹은 감주(甘酒)라고도 하였다.Sikhye is a traditional Korean drink that has been greatly loved by families since the Joseon Dynasty.
식혜의 일반적인 제조방법을 보면, 먼저 체로 친 고운 엿기름 가루를 자루에 담아 약 50℃ 정도의 물에서 추출하여 앙금이 가라앉은 후 고운 체로 걸러 엿기름 물을 준비한다. 준비한 엿기름 물을 멥쌀 또는 찹쌀로 되게 지은 밥에 붓고 4~5시간 동안 50℃로 계속 유지하여 밥알을 삭히는데, 이때 엿기름에 함유되어 있는 효소작용에 의해 밥알이 당화된다.In the general manufacturing method of Sikhye, first, sift the fine malt powder sifted into a bag, extract it from the water at about 50 ° C., and then sediment is settled. The malt is prepared by pouring the prepared malt water into rice cooked with non-glutinous rice or glutinous rice and keeping it at 50 ° C. for 4-5 hours. The rice grains are glycosylated by the enzymatic action contained in the malt.
밥알이 몇개 떠오르면 건져내어 찬물에 헹군 후 받쳐서 물기를 빼고, 밥알을 건져낸 식혜물에 설탕을 넣고 끓인 후 냉각시켜서 식혜를 제조한다.If a few grains come out, scoop them out, rinse them in cold water, and then drain them. Then, add sugar to the brewed foods, boil them, and cool them to make Sikhye.
식혜에 대한 기호성의 증가와 더불어 식혜가 상품화되어 대량 생산, 판매됨에 따라 식혜의 기호성을 증가시키기 위한 연구가 활발히 진행되고 있다.In addition to the increase in palatability for Sikhye, research is being actively conducted to increase palatability of Sikhye as it is commercialized and mass produced and sold.
한편, 종래의 기술로서,On the other hand, as a conventional technique,
대한민국 등록특허공보 제10-0296729호에 마를 첨가하여 제조됨으로써 맛과 향이 향상되고 음용시 인체의 건강을 유지 및 도모시킬 수 있는 식혜가 개시되어 있고,By adding hemp to Korean Patent Publication No. 10-0296729, the taste and aroma are improved, and Sikhye is disclosed to maintain and promote the health of the human body when drinking.
대한민국 공개특허공보 특1998-068217에 영지버섯, 솔닢, 인삼, 칡, 감초 등을 혼합하여 제조됨으로써 향이 유별나고 제조공정이 단순화된 식혜의 제조방법이 개시되어 있고,In the Republic of Korea Patent Publication No. 1998-068217 is prepared by mixing Ganoderma lucidum, Sol 닢, ginseng, 칡, licorice and the like, the manufacturing method of Sikhye is unusual and has a simplified manufacturing process is disclosed,
대한민국 공개특허공보 특1997-0058599호에 인삼이나 오미자를 첨가하여 제조됨으로써 생약성분의 건강기능성 및 독특한 향미가 첨가된 식혜의 제조방법이 개시되어 있고,By manufacturing ginseng or Schisandra chinensis in Republic of Korea Patent Publication No. 1997-0058599 discloses a method of producing Sikhye added the health functional and unique flavor of herbal ingredients,
대한민국 등록특허공보 제10-0173840호에 두충엽, 녹차, 메밀엽, 감잎, 산사자, 동규자 등의 생약재를 첨가하여 제조됨으로써 체중감량 및 고혈압 예방의 효과가 있는 식혜가 개시되어 있다.Sikhye has been disclosed to have the effect of weight loss and prevention of hypertension by adding herbal medicines such as tofu leaf, green tea, buckwheat leaf, persimmon leaf, mountain lion, Dong Kyuja to Republic of Korea Patent Publication No. 10-0173840.
그러나, 암예방 효과가 있는 한방식혜에 관한 것은 종래에 없었다.However, there has been no prior art related to Korean dietary supplement with cancer prevention effects.
이에 본 발명자들은 식혜의 기호성과 함께 암예방에 효과가 있는 기능성 건강 식혜를 제공하기 위하여 거듭 연구하여 왔으며, 그 결과 엿기름 분말에 느릅나무 분말, 치자 분말, 갈근 분말, 뽕잎 분말, 감초 분말 및 생강 분말을 혼합한 후 열수추출하여 얻어지는 엿기름액을 찹쌀, 율무로부터 제조된 식혜밥에 첨가하여 당화시키면, 생약재의 유효성분 식혜로 침출됨으로써, 암예방의 기능성을 보강된 식혜를 제조할 수 있음을 규명하고 본 발명을 완성하게 되었다.Therefore, the present inventors have repeatedly studied to provide functional health Sikhye effective in cancer prevention with the palatability of Sikhye, and as a result, elm powder, gardenia powder, root powder, mulberry leaf powder, licorice powder and ginger powder in malt powder After mixing the malt solution obtained by hot water extraction to glutinous rice, Sikhye rice prepared from Yulmu and saccharifying, by leaching into the active ingredient Sikhye of the herbal medicine, it was found that Sikhye reinforced with the functionality of cancer prevention can be prepared. The present invention has been completed.
따라서, 본 발명의 목적은 생약재가 침출되어 있는 엿기름액을 찹쌀, 율무로부터 제조된 식혜밥에 첨가하여 당화시켜 제조함으로써, 암예방 효과가 있는 한방 식혜 및 그 제조방법을 제공하는 것이다.Accordingly, an object of the present invention is to provide a herbal Sikhye having a cancer prevention effect and a manufacturing method by adding the malt solution from which the herbal medicine is leached to the Sikhye rice prepared from glutinous rice, Yulmu and saccharified.
상기 목적을 달성하기 위하여, 본 발명은,In order to achieve the above object, the present invention,
찹쌀 25 중량부, 율무 25 중량부를 혼합한 후, 100 중량부의 물을 붓고 2시간 동안 실온에서 불린 후, 120℃의 온도에서 10분 동안 증자하여 식혜밥을 준비하는 단계;Mixing 25 parts by weight of glutinous rice and 25 parts by weight of yulmu, pouring 100 parts by weight of water and soaking at room temperature for 2 hours, and then cooking for 10 minutes at a temperature of 120 ° C. to prepare Sikhye rice;
정제수 500 중량부에 엿기름 47 중량부, 느릅나무 껍질 분말 0.5 중량부, 치자 분말 0.5 중량부, 갈근 분말0.5 중량부, 뽕잎 분말 0.5 중량부, 감초 분말 0.5 중량부 및 생강 분말 0.5 중량부를 첨가한 후 60℃의 온도로 2시간 동안 열수추출하여 엿기름액을 얻는 단계; 및47 parts by weight of malt oil, 0.5 parts by weight of elm bark powder, 0.5 parts by weight of gardenia powder, 0.5 parts by weight of root powder, 0.5 parts by weight of mulberry leaf powder, 0.5 parts by weight of licorice powder and 0.5 parts by weight of ginger powder Hot water extraction at a temperature of 60 ° C. for 2 hours to obtain malt solution; And
상기 단계를 통해 준비된 식혜밥과 엿기름액을 혼합한 후 50℃에서 5시간 동안 당화시키는 단계를 포함하는 것을 특징으로 하는 한방 식혜의 제조방법을 제공한다.After mixing the prepared Sikhye rice and malt solution prepared by the above step provides a method for producing herbal Sikhye comprising the step of saccharifying for 5 hours at 50 ℃.
이하, 본 발명의 구성에 대하여 더욱 상세히 설명한다.Hereinafter, the configuration of the present invention will be described in more detail.
본 발명에서 식혜의 기능성을 보강하기 위하여 첨가되는 생약재는 느릅나무 껍질, 치자, 갈근, 뽕잎, 감초 및 생강으로서, 느릅나무 껍질은 치습(治濕)·이뇨제·소종독(消腫毒)에 사용되고, 치자는 불면증과 황달의 치료에 사용하고 소염 ·지혈 및 이뇨의 효과가 있으며, 갈근은 한방에서 발한 ·해열 ·완하제(緩下劑)로서, 고열 ·두통 ·고혈압 ·심부전 ·설사 ·어깨가 결릴 때 등에 사용된다. 뽕잎은 열내림, 기침멎이의 효과가 있으며, 감초는 감미를 증진시키는 효과가 있고, 생강은 소화불량·구토·설사에 효과가 있고, 혈액 순환을 촉진하며, 항염증과 진통 효과가 있다.Herbal medicines added to enhance the functionality of Sikhye in the present invention are elm bark, gardenia, roots, mulberry leaves, licorice and ginger, the elm bark is used for moisturizing, diuretic, small bovine poison (독) , Gardenia is used for the treatment of insomnia and jaundice. It has the effect of anti-inflammatory, hemostasis and diuresis. The roots are sweating, fever, and laxative in Chinese medicine, high fever, headache, hypertension, heart failure, diarrhea, and shoulder Used when Mulberry leaves have the effect of heat lowering, coughing, licorice has the effect of improving sweetness, ginger is effective in indigestion, vomiting, diarrhea, promotes blood circulation, anti-inflammatory and analgesic effect.
본 발명은 엿기름액 제조시에 생약재를 첨가하여 생약재가 첨가된 엿기름액을 제조한다.In the present invention, the malt solution to which the herbal agent is added is prepared by adding the herbal medicine during malt solution preparation.
식혜의 제조 중에는 엿기름 제조시 또는 당화과정시에, 생약재를 첨가하여 식혜제조에 있어 필수적인 엿기름 제조공정과 당화공정에 병행하여 생약재를 열수추출할 수 있는 특징이 있는데, 당화공정에 첨가하는 것 보다 엿기름 제조공정에 생약재를 첨가하는 것이 쓴 맛의 발생이 적고, 따라서 생약성분을 많이 첨가시킬 수 있는 장점이 있다.During the production of Sikhye, during the malt production or saccharification process, it is possible to extract the herbal medicines in parallel with the malt production process and the saccharification process by adding the herbal medicine to the malt production process. The addition of the herbal medicine to the manufacturing process has the advantage of less bitterness, thus adding a large amount of herbal ingredients.
이는 본원발명에서 엿기름 액의 제조시에 온도가 더 높아 열수추출의 효과가 우수하며, 침출과 동시에 엿기름으로부터 유래한 여러 효소들의 작용을 받아 생약재로부터 유효성분들을 보다 효율적으로 침출시킬 수 있기 때문이다.This is because, in the present invention, the temperature is higher during the production of the malt solution, the effect of hot water extraction is excellent, and at the same time it is possible to more efficiently leach the active ingredient from the herbal medicine by the action of various enzymes derived from malt at the same time leaching.
또한, 본 발명은 별도의 추출공정 없이 생약재로부터 유효성분을 추출해 낼 수 있으므로, 공정을 단순화시키는 장점도 있다.In addition, the present invention can extract the active ingredient from the herbal medicine without a separate extraction process, there is an advantage to simplify the process.
본 발명의 건강 식혜에서 사용되는 생약재들은 그 형태에 특별히 한정되지 않으며, 예를 들어 유효성분의 침출이 용이하게 이루어지도록 수분함량이 10% 이하가 되도록 건조된 후, 0.1∼0.5cm로 분쇄된 것을 사용한다.Herbal medicines used in the health Sikhye of the present invention is not particularly limited to the form, for example, the water content is dried to 10% or less so that the leaching of the active ingredient is easily made, and then pulverized to 0.1 ~ 0.5cm use.
또한, 본 발명에 사용되는 생약재들은 고유의 맛이 강하고 특유의 자극적인 향취를 갖고 있어 식혜의 전반적인 기호성을 해칠 수 있으므로, 엿기름 물 중량에 대해 균등하게 3.0중량% 첨가한다. 한편, 제조된 한방식혜에 기호에 따라 감미료를 추가로 첨가하여 섭취할 수 있다.In addition, the herbal medicines used in the present invention have a strong intrinsic taste and a characteristic irritating odor, which may impair the overall palatability of Sikhye, so that 3.0 wt% of malt oil is added equally to the weight of water. On the other hand, the prepared herbal foods can be ingested by adding an additional sweetener according to preference.
상기와 같이 제조되는 본 발명의 식혜는 하기 실험예에 의한 실험결과 암발생을 억제하는 효과가 발생한다.Sikhye of the present invention prepared as described above has the effect of inhibiting cancer occurrence as a result of the experiment by the following experimental example.
이하, 본 발명의 구성을 하기 실시예를 들어 더욱 상세히 설명하지만, 본 발명의 권리범위가 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the configuration of the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited only to these examples.
실시예1: 본원발명인 한방 식혜의 제조Example 1: Preparation of herbal Sikhye of the present invention
찹쌀 25 g, 율무 25 g을 혼합한 후, 100 g의 물을 붓고 2시간 동안 실온에서 불린 후, 120℃의 온도에서 10분 동안 증자하여 식혜밥을 준비하였다.After mixing 25 g of glutinous rice and 25 g of yulmu, 100 g of water was poured and soaked at room temperature for 2 hours, and then cooked for 10 minutes at a temperature of 120 ° C. to prepare Sikhye rice.
또한, 정제수 500 g에 엿기름 47 g, 느릅나무 껍질 분말 0.5 g, 치자 분말 0.5 g, 갈근 분말 0.5 g, 뽕잎 분말 0.5 g, 감초 분말 0.5 g 및 생강 분말 0.5 g을 첨가한 후 60℃의 온도로 2시간 동안 열수추출하여 엿기름액을 얻었다.In addition, to 500 g of purified water, 47 g of malt oil, 0.5 g of elm bark powder, 0.5 g of gardenia powder, 0.5 g of root powder, 0.5 g of mulberry leaf powder, 0.5 g of licorice powder, 0.5 g of licorice powder and 0.5 g of ginger powder were added, and then the temperature was 60 ° C. Hot water was extracted for 2 hours to obtain malt solution.
상기 2단계를 통해 준비된 식혜밥과 엿기름액을 혼합한 후 50℃에서 5시간 동안 당화시켜 한방 식혜를 제조하였다.After mixing the Sikhye rice and malt solution prepared in the above step 2 and saccharified for 5 hours at 50 ℃ to prepare a herbal Sikhye.
비교예1: 한약재를 첨가하는 것을 빼고는 본원발명과 동일한 과정으로 제조된 일반 식혜의 제조Comparative Example 1: Preparation of general Sikhye prepared by the same process as the present invention except adding the herbal medicine
엿기름액의 제조에 있어, 한약재를 첨가하는 것을 제외하고는 실시예 1과 동일한 방법으로 일반 식혜를 제조하였다. 다만, 이때 첨가되는 엿기름이 양은 50 g으로 하였다.In the production of malt, general Sikhye was prepared in the same manner as in Example 1 except for adding a herbal medicine. However, the amount of malt added at this time was 50 g.
실험예 1: 관능검사Experimental Example 1: sensory test
전문 관능검사 요원 10명을 대상으로 하여, 실시예1 및 비교예1의 식혜에 대하여 식혜의 향미를 다음의 평가기준으로 점수화하였다. 평가는 3회에 걸쳐 반복실시하였으며 그 값을 표 1에 나타내었다.The taste of Sikhye was scored based on the following evaluation criteria for Sikhye of Example 1 and Comparative Example 1, targeting 10 professional sensory test personnel. The evaluation was repeated three times and the values are shown in Table 1.
상기 표 1의 결과로부터, 본 발명의 한방 식혜는 통상의 예측과 달리 한약재의 첨가에도 불구하고, 일반 식혜와 거의 비슷한 정도의 향미를 갖고 있으며, 은은하게 나는 한약 특유의 향으로부터 건강식품이라는 인식이 생기게 함으로써, 오히려 바람직스러운 풍미를 나타낸다는 것을 확인할 수 있었다.From the results of Table 1, the herbal Sikhye of the present invention, unlike the conventional prediction, despite the addition of herbal medicines, has almost the same flavor as general Sikhye, and I tend to be aware of the health food from the unique flavor of Chinese medicine By doing this, it turned out that the rather favorable flavor is shown.
실험예2: 본 발명 한방 식혜의 고형암 성장저지 효과Experimental Example 2: Effect of the Herbal Medicine Sikhye on Inhibiting Solid Cancer Growth
본 실험예에서는 상기 실시예1로부터 얻은 식혜(이하, "한방식혜"라 한다)와 비교예1로부터 얻은 식혜(이하, "일반식혜"라 한다)에 의한 항종양효과를 보기 위하여 Balb/c 마우스의 왼쪽 서혜부 피하에 'sarcoma-180' 종양세포를 이식시킨 후 20일 동안 0.25 mg/kg 시료를 투여하고, 이로부터 32일이 지난 다음 마우스를 해부하여 종양을 분리하고 그 무게를 측정하였다.In the present experimental example, Balb / c mouse to see the anti-tumor effect by Sikhye obtained from Example 1 (hereinafter referred to as "Hansikhye") and Sikhye obtained from Comparative Example 1 (hereinafter referred to as "General Sikhye") After implanting 'sarcoma-180' tumor cells in the left inguinal subcutaneous of the 0.25 mg / kg sample was administered for 20 days, after 32 days from the mouse was dissected tumor was isolated and weighed.
실험결과, 표 2에 나타낸 바와 같이 종양세포만 이식한 대조군(S-180+PBS, 시료대신 동량의 PBS만 투여)은 종양의 무게가 5.98g인 반면, 한방식혜를 주사한 군(S-180+FS)은 4.45g으로 감소하여 현저한 종양생성 억제효과를 보였으며, 일반식혜를 주사한 군(S-180+CS)은 5.90g으로 대조군과 큰 차이를 보이지 않았다.As a result, as shown in Table 2, the control group implanted with only tumor cells (S-180 + PBS, administered with the same amount of PBS instead of the sample) had a tumor weight of 5.98g, whereas the group injected with Hansikhye (S-180 + FS) decreased to 4.45g, showing significant tumor suppression effect, and the general Sikhye injected group (S-180 + CS) was 5.90g, which was not significantly different from the control group.
따라서, 한방식혜가 고형암 성장저지 효과가 있음을 알 수 있었다.Therefore, it was found that Han, Hye-hye had a solid growth inhibition effect.
실험예3: 식혜를 식이로 급여한 마우스 각 장기 중량변화Experimental Example 3 Weight Changes of Organs in Mice fed Sikhye
본 발명 한방식혜와 일반식혜가 종양 외에 다른 기타 기관에서의 작용을 측정하기 위하여, 대조군(Control)은 자유식이만을 시켰고, 종양세포대조군(S-180+PBS)에는 자유식이를 시키고 주사로 PBS를 투여하였고, 처리군은 자유식이를 주고 주사로 종양세포대조군과 동량인 식혜물을 종양세포(Sarcoma-180 세포)이식 후 상기 실험예 2와 동일하게 시료를 20일 동안 투여하고 각 장기의 중량을 측정하였다.In order to measure the effects of the present invention, Hansikhye and general Sikhye in other organs other than the tumor, the control (Control) was only free diet, the tumor cell control group (S-180 + PBS) free diet and injection PBS The treated group was given a free diet and injected with the same amount of tumor cells (Sarcoma-180 cells) after transplanting the sikhye with the same amount of tumor cell control group, the sample was administered for 20 days and the weight of each organ Measured.
실험결과, 표 3에 나타낸 바와 같이, 먼저 대사과정 중에 생기는 여러 유해한 물질들의 해독작용을 담당하는 간의 중량비는 종양세포만 이식한 대조군(S-180+PBS)과 일반식혜를 주사한 군(S-180+CS)이 한방식혜를 주사한 군(S-180+FS)에 비해 다소 높았고, 비장의 경우도 식혜를 주사한 군이 종양세포만 이식한 대조군에 비해 낮았으나, 일반식혜를 주사한 군과는 큰 차이는 없었다.As a result, as shown in Table 3, the weight ratio of liver, which is responsible for the detoxification of various harmful substances generated during metabolic processes, was the control group implanted with tumor cells only (S-180 + PBS) and the group injected with general Sikhye (S- 180 + CS) was slightly higher than S-180 + FS, and spleen was lower than the control group implanted with tumor cells. There was no big difference.
실험예4: 본 발명 한방식혜와 일반식혜의 면역활성 증가 효과Experimental Example 4: Effect of Increased Immune Activity of the Invention Herbal Medicine and General Sikhye
본 실험예에서는 실험예3과 동일한 방법으로 종양세포를 이식하고 20일 동안 본 발명 한방식혜와 일반식혜 시료를 투여한 후 각 마우스의 비장을 무균적으로 적출하여 비장의 자연살해(natural killer;NK) 세포 활성을 살펴보았다.In this experimental example, the tumor cells were transplanted in the same manner as in Experiment 3, and the spleens of each mouse were sterilely extracted after 20 days of administration of the present invention, the method of the present invention, and the natural killer (NK) of the spleen. ) Cell activity was examined.
자연살해세포의 활성을 분석하기 위해 먼저 이펙터 세포(Effector cell)인 NK세포를 준비하였다. 마우스의 비장을 클린 벤치(clean bench) 내에서 무균적으로 적출하여 페니실린(100U/mL), 스트렙토마이신(100㎍/mL)을 함유한 5mL의 RPMI 1640 배지로 3회 세척한 후 곱게 마쇄하였다.In order to analyze the activity of natural killer cells, first, effector cells (NK cells) were prepared. The spleens of the mice were aseptically extracted in a clean bench, washed three times with 5 mL of RPMI 1640 medium containing penicillin (100 U / mL) and streptomycin (100 μg / mL), and then finely ground.
이 세포 부유액을 70㎛ 나일론 메쉬로 여과시켜서 원심분리하여 림프구를 모은 다음 이것을 같은 배지에 부유시켰다.The cell suspension was filtered through a 70 μm nylon mesh, centrifuged to collect lymphocytes, and then suspended in the same medium.
이것을 다시 히스토파쿠에-1077(histopaque-1077)을 이용하여 원심분리(500×g, 30 min, 18℃)를 통해서 림프구를 분리해냈다. 준비한 세포를 10% FCS, 2mM L-글루타민, 페니실린(100U/mL), 스트렙토마이신(100㎍/mL)을 함유한 RPMI 1640 배지에 재현탁시켰다.Lymphocytes were isolated by centrifugation (500 × g, 30 min, 18 ° C.) using histopacque-1077 (histopaque-1077). The prepared cells were resuspended in RPMI 1640 medium containing 10% FCS, 2 mM L-glutamine, penicillin (100 U / mL), streptomycin (100 μg / mL).
이것을 37℃, CO2배양기에서 1~2 시간 배양시켜서 세포가 배양 플라스크(6cm페트리디쉬)에 부착되도록 하였다. 비부착성 자연살해 세포를 원심분리하여 수집한 후 배양배지에 재현탁시킨 다음 적정 세포수를 계수하여 사용하였다. 이어서, 자연살해 세포의 세포파괴활성은 MTT 방법으로 분석하였다.This was incubated for 1 to 2 hours at 37 ° C. in a CO 2 incubator to allow cells to adhere to the culture flask (6 cm Petri dish). Non-adhesive natural killer cells were collected by centrifugation, resuspended in culture medium, and the appropriate number of cells was counted. Subsequently, cell destruction activity of natural killer cells was analyzed by MTT method.
Yac-1 마우스 림포마 세포(Yac-1 mouse lymphoma cell)는 타겟 세포(target cell)로 사용하였다. Yac-1 세포는 NK 세포 활성을 측정하는데 가장 편리한 타겟 세포주이다.Yac-1 mouse lymphoma cells were used as target cells. Yac-1 cells are the most convenient target cell line for measuring NK cell activity.
Yac-1 세포는 10% FCS, 2mM L-글루타민 페니실린(100U/mL), 스트렙토마이신(100㎍/mL)를 함유한 RPMI 1640 배지에 5×104cells/mL의 밀도가 되도록 희석한 후 각 웰에 50㎕씩 가하였다.Yac-1 cells were diluted to a density of 5 × 10 4 cells / mL in RPMI 1640 medium containing 10% FCS, 2 mM L-glutamine penicillin (100 U / mL) and streptomycin (100 μg / mL). 50 μl was added to the wells.
그리고, NK 세포×107cells/mL의 NK 세포 활성 분석을 위해서 이펙터 세포와 Yac-1 세포 각각 50㎕씩을 96웰 플레이트에 첨가하였다.In addition, 50 μl of effector cells and Yac-1 cells were added to 96-well plates for NK cell activity analysis of NK cells × 10 7 cells / mL.
이를 37℃, CO2배양기 안에서 3일간 배양시킨 후 MTT(5mg/mL) 용액을 10㎕씩 각 웰에 가한 다음 37℃에서 4시간 배양하였다. 여기에 SDS(10% in 0.02N HCl)을 25㎕ 첨가하여 실온에서 30분간 발색시킨 후 540nm에서 OD를 측정하였다. 세포 독성 퍼센트는 하기 공식에 의해 계산하였다.After incubating for 3 days at 37 ° C. in a CO 2 incubator, 10 μl of MTT (5 mg / mL) solution was added to each well and incubated at 37 ° C. for 4 hours. 25 μl of SDS (10% in 0.02N HCl) was added thereto, followed by color development at room temperature for 30 minutes, and OD was measured at 540 nm. Percent cytotoxicity was calculated by the following formula.
실험결과, 한방식혜투여군(S-180+FS)이 55.42%의 저해효과를 나타내 가장 높았으며 대조군은 49.35%, 종양세포만을 이식한 경우는 31.52%, 종양세포를 이식하고 일반식혜를 투여한 군은 33.42%를 나타냈다. 상기 결과에서 일반식혜를 투여한 군은 NK세포 면역활성이 낮아 종양세포만 이식한 군과 비슷하게 나타났다.The results showed that the S-180 + FS group showed the highest inhibitory effect of 55.42%, 49.35% in the control group, 31.52% in the transplantation of tumor cells only, and transplanted with the general Sikhye group. Was 33.42%. In the above results, the group receiving general Sikhye showed low NK cell immune activity, similar to the group transplanted with only tumor cells.
실험예5: 본 발명 한방식혜와 일반식혜에 의한 마우스 간내의 글루타치온-S-트랜스퍼라아제 활성 변화Experimental Example 5: Glutathione-S-transferase Activity Changes in Mouse Liver by Invention of Korean Invention
간에서 일어나는 대사효소계의 'phaseⅡ' 단계는 내인성 물질이나 외부에서 투여되어지는 독성물질을 포함하거나 수용성 물질로 전환시켜 체외로 배출 시킴으로서 이물질을 제거하는 작용을 하는데 글루타치온-S-트랜스퍼라아제(glutathione-S-transferase)는 환원 글루타치온(reduced glutathione)을 이용하여 체내 독성물질과 과산화물질을 전이, 배설함으로서 무독화에 관여하는 효소이다.The phase II phase of the metabolic enzyme system in the liver removes foreign substances by including endogenous or externally administered toxic substances or by converting them into water-soluble substances to release them to the body. Glutathione-S-transferase (glutathione- S-transferase) is an enzyme that is involved in detoxification by transferring and excreting toxic substances and peroxides in the body using reduced glutathione.
본 실험예에서는 상기 실시예 4와 같이 시료와 식이를 공급한 쥐의 간내 글루타치온-S-트랜스퍼라아제 활성을 측정하였다.In this experimental example, the glutathione-S-transferase activity in the rats fed the sample and the diet was measured as in Example 4.
먼저, 글루타치온-S-트랜스퍼라아제(GST) 활성을 측정하기 위해 마우스를 치사시킨 후 4℃ 이하의 생리 식염수로 간을 관류하여 간내에 남아 있는 혈액을 제거한 후 간장을 적출하였다.First, in order to measure glutathione-S-transferase (GST) activity, mice were killed and the liver was perfused with physiological saline of 4 ° C. or lower to remove blood remaining in the liver, and the liver was extracted.
간조직 1g 당 0.1M 인산칼륨 버퍼(potassium phospate buffer, pH 7.4)를 가하여 빙냉하에서 글라스 테플론 호모게나이저(glass teflon omogenizer)로 마쇄하였다.0.1 M potassium phosphate buffer (pH 7.4) was added per 1 g of liver tissue, and the mixture was ground with a glass teflon omogenizer under ice cooling.
이 마쇄액을 호모게네이트(homogenate) 분획으로 하였으며, 이것을 13,000rpm에서 10분간 원심분리하여 핵 및 미마쇄세포부분을 제거하고 다시 105,000×g에서 1시간 동안 초원심분리하여 얻은 상등액을 사이토졸 분획으로 하였다.The ground liquor was used as a homogenate fraction, which was centrifuged at 13,000 rpm for 10 minutes to remove nuclei and unbroken cell sections, and the supernatant obtained by ultracentrifugation at 105,000 × g for 1 hour was used as a cytosol fraction. It was made.
0.1M 인산칼륨버퍼(pH 6.5) 중에 0.04M 환원 글루타치온 75㎕을 가한 후 효소액을 0.1mL 넣고 블랭크에는 20% 트리크로아세트산 0.5mL를 가해 효소를 실활시키고 시료는 25℃에서 5분간 반응시킨 후 블랭크와 시료 각각에 0.12M 1-클로로-2,4-디니트로벤젠 25㎕를 가하여 25℃에서 2분간 반응시킨 다음, 시료에 20% 트리클로로아세트산을 가해 반응을 완결시킨 후 원심분리하여 얻은 상등액을 340nm에서 흡광도를 측정한 다음 1-클로로-2,4-디니트로벤젠의 몰 흡광계수 9.6mM1cm-1을 이용하여 활성도를 산정하였다.75 μl of 0.04 M reduced glutathione was added to 0.1 M potassium phosphate buffer (pH 6.5), 0.1 mL of enzyme solution was added, and 0.5 mL of 20% trichloroacetic acid was added to the blank to inactivate the enzyme, and the sample was reacted at 25 ° C. for 5 minutes. 25 μl of 0.12M 1-chloro-2,4-dinitrobenzene was added to each sample and reacted at 25 ° C. for 2 minutes. 20% trichloroacetic acid was added to the sample to complete the reaction, followed by centrifugation. After absorbance was measured at 340 nm, the activity was calculated using a molar extinction coefficient of 1-chloro-2,4-dinitrobenzene 9.6 mM 1 cm -1 .
효소 활성의 단위는 1분간 mg 단백질이 생성한 2,4-디니트로벤젠-글루타치온의 nmole 수로 표시하였다.Units of enzymatic activity were expressed as nmole number of 2,4-dinitrobenzene-glutathione produced by mg protein for 1 minute.
실험결과, 글루타치온-S-트랜스퍼라아제 활성은 종양세포를 이식하지 않은 대조군이 391.5nmol/mg protein/min이었으며 종양세포를 이식한 대조군(S-180 + PBS)에서는 282.5nmol/mg protein/min으로 떨어졌다.As a result, glutathione-S-transferase activity was 391.5nmol / mg protein / min in the control group without transplanting tumor cells and 282.5nmol / mg protein / min in the control group in which tumor cells were transplanted (S-180 + PBS). fell.
일반식혜를 주사한 군(S-180 + CS)에서는 275.4nmol/mg protein/min으로 종양세포를 이식한 대조군보다 오히려 낮은 수치를 보였으나, 한방식혜를 주사한 군(S-180 + FS)에서는 512.5nmol/mg protein/min으로 종양세포를 이식한 대조군에 비해 글루타치온-S-트랜스퍼라아제의 활성이 현저히 높은 것으로 나타났다.In the group receiving general Sikhye (S-180 + CS), it was lower than the control group implanted with tumor cells at 275.4 nmol / mg protein / min, but in the group receiving Han Sikhye (S-180 + FS) The activity of glutathione-S-transferase was significantly higher than that of the control group transplanted with 512.5 nmol / mg protein / min.
실험예6: 본 발명 한방식혜와 일반식혜에 의한 마우스 간조직내의 글라이코겐 분포조사Experimental Example 6: Glycogen Distribution in Mouse Liver Tissues of the Invention
본 실시예에서는 상기 실험예 4와 같이 시료와 식이를 공급한 쥐의 간조직내 글라이코겐 분포를 조사하였다. 쥐의 간을 절취하여 4% 파라포름알데하이드 인 포스페이트-버퍼 사린(paraformaldehyde in phosphate-buffered saline;PBS)에 4℃, 12시간 고정하여 순차적인 탈수와 투명화를 거쳐 파라핀(paraffin)에 포매한 후 6㎛ 연속절편을 제작하였다.In this example, the glycogen distribution in the liver tissue of rats fed the sample and the diet was examined as in Experimental Example 4. The rat liver was excised and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) at 4 ° C. for 12 hours, followed by sequential dehydration and clarification, and embedded in paraffin. A micrometer continuous section was produced.
간의 조직학적 변화와 글라이코겐 분포관찰을 위해 탈 파라핀한 후 헤마토실린-에오신(hematoxylin-eosin:H-E) 염색과 PAS(periodic acid Schiff)반응을 실시하였다.Deparaffinization, hematoxylin-eosin (H-E) staining and periodic acid Schiff (PAS) reaction were performed for histological changes and glycogen distribution.
실험결과, 종양세포 'sarcoma-180'를 이식하고 PBS를 투여한 군(S-180 + PBS)은 간 특유의 간소엽 형태를 갖추고 있으나, 약한 혼탁종창, 수포성 변성, 지방변성, 커퍼(Kupffer) 세포변화, 국소적 괴사 등의 변화와 함께 호산성 세포도 일부 관찰되는 등 간세포의 변화를 보이고 있다.As a result, the tumor cells 'sarcoma-180' transplanted and PBS-administered group (S-180 + PBS) had liver-specific hepatic lobules, but had weak turbid swelling, bullous degeneration, fat degeneration and cupper (Kupffer). Hepatic cell changes, such as changes in cellular and local necrosis, are also observed.
대조군에서 위와 같은 조직학적 변화가 현저히 증가할 뿐만 아니라 호산성세포와 핵이 농염되는 세포가 증가하는 등 많은 변화를 보이는데 특히 간소엽 주변구역에서 심하였다.In the control group, not only did the histological changes significantly increase, but also increased the number of eosinophilic cells and the cells of the nucleus-concentrating cells, especially in the periphery of the hepatic lobe.
일반식혜를 식이한 경우(S-180 + CS)는 조직학적 변화가 S-180 + PBS와 유사하였으며, 한방식혜를 식이한 경우(S-180 + FS)는 지방변성, 커퍼(Kupffer) 세포변화, 국소적 괴사에서 다소 적은 변화를 보였다.Histologic changes were similar to that of S-180 + PBS in the case of dieting general Sikhye (S-180 + CS), and in the case of dieting Han Sikhye (S-180 + FS), fat degeneration and cupper cell changes were observed. However, there was a slight change in local necrosis.
이를 표 4에 정리하였다.This is summarized in Table 4.
글라이코겐 분포는 정상적인 간조직에 비해 'S-180 + PBS'의 간소엽 주변구역과 중간구역에서 감소하며 'S-180 + CS'와 'S-180 + FS'도 정상군에 비해 간소엽 주변구역에서 다소 감소하였다. 이는 일반식혜보다 본 발명 한방식혜가 간세포를 덜 손상시킴을 나타낸다. 이는 표 5에 정리하였다.Glycogen distribution was decreased in the surrounding and intermediate regions of 'S-180 + PBS' compared to normal liver tissue, and 'S-180 + CS' and 'S-180 + FS' were also compared to normal liver tissue. It decreased slightly in the surrounding area. This indicates that the herbal dietary invention of the present invention causes less damage to hepatocytes than general sikhye. This is summarized in Table 5.
실험예7: 본 발명 한방식혜와 일반식혜에 의한 마우스 간조직의 면역조직학적 반응Experimental Example 7 Immunohistologic Responses of Mouse Liver Tissues by the Invention of the Invention
본 실험예에서는 상기 실험예 4와 같이 시료와 식이를 공급한 쥐의 간조직에 대한 종양관련 단백질의 면역조직화학적 반응을 보기 위해 각 종양과 관련된 단백질에 대한 면역조직학적 관찰을 위해 탈파라핀하여 10mM 소듐 시트레이트 버퍼(pH 6.0)에서 95℃ 5분간 처리하였고, 다시 실온에서 동일 버퍼에 20분 두었다.In this experimental example, in order to see the immunohistochemical response of tumor-associated proteins to liver tissues of rats fed with a sample and a diet as in Experiment 4, deparaffinizing 10 mM for immunohistochemical observations of proteins associated with each tumor Treatment was performed at 95 ° C. for 5 minutes in sodium citrate buffer (pH 6.0) and again placed in the same buffer at room temperature for 20 minutes.
이를 3% 메탄올 하이드로전 퍼옥사이드에 30분간 실온에서 처리하고 PBS(0.01M, pH 7.5)로 5분간 3회 세척한 후 비특이성 반응을 없애기 위하여, 'goat normal serum(Vector Lab., PK-6101)'으로 실온에서 30분간 처리하였다.This was treated with 3% methanol hydroperoxide at room temperature for 30 minutes and washed three times with PBS (0.01M, pH 7.5) three times for 5 minutes to remove the non-specific reactions, 'goat normal serum (Vector Lab., PK-6101). Treated at room temperature for 30 minutes.
이를 제거하고 'Santa Cruz Biotechnology Inc' 제품의 Bax(sc-493), Bcl-2(sc-783), Rb(sc-050), c-fos (sc-253), c-jun(sc-1694)을 500:1로 희석하여 4℃ 습실에 16시간 동안 반응시켰다.Removed and Bax (sc-493), Bcl-2 (sc-783), Rb (sc-050), c-fos (sc-253), c-jun (sc-1694) from Santa Cruz Biotechnology Inc. ) Was diluted to 500: 1 and reacted in a 4 ° C wet room for 16 hours.
PBS로 세척하고 'biotinylated anti-rabbit lgG(Vector Lab., PK-6101)'를 실온에서 30분 동안 반응시켰으며, PBS로 세척하고 ABC 키트(avidin-biotin-peroxidae complex, vector Lab., PK-6101)에 실온에서 60분간 반응시켰다.Washed with PBS and reacted 'biotinylated anti-rabbit lgG (Vector Lab., PK-6101)' for 30 minutes at room temperature, washed with PBS and ABC kit (avidin-biotin-peroxidae complex, vector Lab., PK- 6101) at room temperature for 60 minutes.
다시 PBS로 세척한 후 'DAB substract' 키트(vector Lab., SK-4100)로 실온에서 5분간 발색시켰다. 증류수로 세척하여 'Mayer's hematoxylin'으로 대조 염색한 후 광학현미경하에서 반응정도를 판정하였다.After washing with PBS again, it was developed for 5 minutes at room temperature with a 'DAB substract' kit (vector Lab., SK-4100). After washing with distilled water, control dyeing with 'Mayer's hematoxylin' was carried out to determine the degree of reaction under an optical microscope.
실험결과, 간세포에 대한 종양관련 단백질의 면역조직화학적 반응을 보면 6가지 항체중 Bax, Rb, c-fos에만 반응을 나타내며 세포질에 비해 핵에서 강한 반응을 보였으며 일부 간세포사이의 염증세포에서도 반응을 나타내었다.As a result, immunohistochemical reactions of tumor-associated proteins against hepatocytes showed only Bax, Rb, and c-fos among six antibodies, and showed stronger responses in the nucleus than cytoplasm, and also in inflammatory cells between some hepatocytes. Indicated.
Bax는 핵에서만 반응을 나타내며 정상군에 비해 'S-180 + PBS'와 'S-180 + CS'는 감소하였으며 한방식혜인 'S-180 + FS'에서는 감소정도가 적었다.Bax reacts only in the nucleus and decreases in 'S-180 + PBS' and 'S-180 + CS' compared to the normal group.
Rb는 핵과 세포질 모두에서 정상군에 비해 'S-180 + PBS'와 'S-180 + CS'의 경우에 증가하여 특히 중심정맥주위 간세포의 세포질의 변화가 심하였으나 한방식혜인 'S-180 + FS'의 경우는 세포질의 변화는 적었다.Rb increased in the nucleus and cytoplasm of S-180 + PBS and S-180 + CS compared to the normal group, especially in the cytoplasm of central venous hepatocytes. In the case of FS ', cytoplasmic change was small.
c-fos는 정상군의 핵과 세포질에 비해 'S-180 + PBS'에서 증가하는데 일반식혜 'S-180 + CS'와 한방식혜 'S-180 + FS'에서도 대조군과 유사하게 증가하였다. 이를 표 6에 정리하였다.c-fos was increased in 'S-180 + PBS' compared to the nucleus and cytoplasm of normal group, but also increased similarly to control group in 'S-180 + CS' and 'S-180 + FS'. This is summarized in Table 6.
이상 상기에서 살펴본 바와 같이, 본 발명은 엿기름 분말에 느릅나무 분말,치자 분말, 갈근 분말, 뽕잎 분말, 감초 분말 및 생강 분말을 혼합한 후 열수추출하여 얻어지는 엿기름액을 찹쌀, 율무로부터 제조된 식혜밥에 첨가하여 당화시킴으로써 암예방의 기능성을 보강된 식혜를 제조할 수 있는 뛰어난 효과가 있으므로, 건강식품 산업상 매우 유용한 것이다.As described above, the present invention is a Sikhye rice prepared from glutinous rice, yulmu the malt solution obtained by hot water extraction after mixing the elm powder, gardenia powder, brown root powder, mulberry leaf powder, licorice powder and ginger powder to malt powder It is very useful in the health food industry because it has an excellent effect to produce Sikhye reinforced with the functionality of cancer prevention by adding to saccharification.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0011230A KR100533284B1 (en) | 2003-02-22 | 2003-02-22 | Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0011230A KR100533284B1 (en) | 2003-02-22 | 2003-02-22 | Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040075643A true KR20040075643A (en) | 2004-08-30 |
KR100533284B1 KR100533284B1 (en) | 2005-12-05 |
Family
ID=37361894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0011230A KR100533284B1 (en) | 2003-02-22 | 2003-02-22 | Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100533284B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1845806A1 (en) * | 2005-02-04 | 2007-10-24 | Heon Sang Jeong | Drinking water for a diabetic and manufacturing process thereof |
JP2008530000A (en) * | 2005-02-04 | 2008-08-07 | チュンブク ナショナル ユニヴァーシティ インダストリー アカデミック コーポレイション ファウンデーション | Drinking water for diabetics and method for producing the same |
KR100941160B1 (en) * | 2009-09-18 | 2010-02-10 | 주식회사 경희매니지먼트컴퍼니 | Preparation of fermented rice punch |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100880849B1 (en) | 2007-06-08 | 2009-01-30 | 오현경 | Sweet rice drink with Licorice and Angelica gigas Nakai |
KR100996952B1 (en) | 2008-02-28 | 2010-11-29 | 이명예 | The Shike added with arrowroot-Chungkukchang reinforced isoflavone and a preparation method thereof |
KR101321769B1 (en) | 2010-11-26 | 2013-10-25 | 경상북도(농업기술원) | Manufacture method of rice juice by oriental medicine |
-
2003
- 2003-02-22 KR KR10-2003-0011230A patent/KR100533284B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1845806A1 (en) * | 2005-02-04 | 2007-10-24 | Heon Sang Jeong | Drinking water for a diabetic and manufacturing process thereof |
JP2008530000A (en) * | 2005-02-04 | 2008-08-07 | チュンブク ナショナル ユニヴァーシティ インダストリー アカデミック コーポレイション ファウンデーション | Drinking water for diabetics and method for producing the same |
EP1845806A4 (en) * | 2005-02-04 | 2010-09-29 | Nat Univ Chungbuk Ind Acad | Drinking water for a diabetic and manufacturing process thereof |
KR100941160B1 (en) * | 2009-09-18 | 2010-02-10 | 주식회사 경희매니지먼트컴퍼니 | Preparation of fermented rice punch |
Also Published As
Publication number | Publication date |
---|---|
KR100533284B1 (en) | 2005-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7471393B2 (en) | Tea composition having preventive or ameliorative effects on respiratory diseases and pharmaceutical composition containing the same | |
CN102209550A (en) | Composition for cancer prevention or treatment containing as active ingredient plant stem cell line derived from cambium of panax ginseng including wild ginseng or ginseng | |
AU2014284932B2 (en) | Pharmaceutical composition for promoting bone tissue formation, containing Stauntonia hexaphylla leaf extract as active ingredient | |
KR101011703B1 (en) | Anti-hepatic cancer composition comprising extracts from pear and process for preparing the same | |
CN109232760A (en) | Phellinus protect liver polysaccharide PPB-2 and preparation method thereof | |
KR100533284B1 (en) | Method for production of a sweet drink made from fermented rice with anti-cancerous effect by adding herb remedies and a sweet drink thereof | |
CN104093411B (en) | Composition containing chlorella extract, for preventing or treating liver diseases | |
KR20080018676A (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and propolis and process for preparing the same | |
KR101830048B1 (en) | Food composition for improvement obesity or improvement hyperlipidemic with the extract of Terminalia chebula fruit and Phyllanthus emblica | |
CN106421208B (en) | Pharmaceutical composition with chemical liver injury resistance function and preparation method thereof | |
CN112741851A (en) | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules | |
CN114989258B (en) | Application of plant extract composition in preparing product for treating constipation and reducing weight | |
KR100597800B1 (en) | Composition comprising the extract of crude drug extract for improving liver function and alleviating hangover syndrome | |
KR20110049129A (en) | Composition of anti-cancer comprising ulmus arvifolia jacq extract | |
KR100396841B1 (en) | Composition of season for Danmuji with anticancerous function and Danmuji thereof | |
KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
CN101947232B (en) | Use of cactus pear fruit polysaccharides in preparation of medicaments or health-care products | |
KR102261920B1 (en) | Composition comprising Astragali radix derivatives and Lithospermi radix derivatives for preventing and treating liver injury | |
KR20200000174A (en) | Composition for prevention, improvement or treatment of liver fibrosis or cirrhosis including Allium senescens L. Extract | |
KR100553982B1 (en) | Composition comprising the extracts of Cucumis melon Linn. var. ma-gua, Ixeris dentata and Youngia sonchifolia for therapy against chronic viral hepatitis diseases | |
KR102490206B1 (en) | Composition for preventing, ameliorating or treating benign prostatic hyperplasia comprising Viscum album extract as an active ingredient | |
KR102383063B1 (en) | Natural fermentation vinegar using dendropanax morbiferus and dropwort, Manufacturing method thereof, and functional health food for protecting and improving a liver and kidney | |
KR101991914B1 (en) | Laminaria japonica kyeongokgo having excellent estrogen activities and manufacturing method thereof | |
CN102397287B (en) | Application of opuntia ficus-indica polysaccharide in preparation of medicine with hypolipidemic effect | |
KR20230105888A (en) | Crushed and dried Keumhwagyu beef and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121128 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141127 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161128 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171129 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 14 |